---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Product comparison"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Product comparison. Topics: Approved pharmacotherapies for TRD in the United States, Comparators in the ICER assessment of synthetic psilocybin, Dosing frequency compared with esketamine: company statements, Session monitoring time compared with esketamine: six hours and two hours, and 7 further topics. 11 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/product-comparison"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Approved pharmacotherapies for TRD in the United States

> “Currently, only two pharmacotherapies are approved for TRD in the U.S.: Spravato (esketamine), marketed by Janssen, which is an NMDA receptor antagonist; and olanzapine and fluoxetine hydrochloride capsules, which are available generically.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.2.14-2"></a>

### Comparators in the ICER assessment of synthetic psilocybin

> “Data permitting, we intend to compare the agent to:”
> “Esketamine (SPRAVATO®, Janssen) / Intravenous (IV) ketamine, an anesthetic agent used off-label for TRD”
> “Repetitive Transcranial Magnetic Stimulation (rTMS)”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-2.1.2.14-3"></a>

### Dosing frequency compared with esketamine: company statements

> “Today, less than 3% of these patients are accessing the only marketed and approved TRD treatment, SPRAVATO, due largely to the burden associated with the required frequency of dosing.”
> “COMP360 is poised to lead a profound shift in mental health care, moving beyond the daily antidepressants or frequent dosing required with SPRAVATO toward an option involving just a few treatments a year, fundamentally changing the way that patients living with depression are cared for.”
> “of being able to see these results within 24 hours, but then being able to maintain durability out to 12 months with just a few treatments versus the 36-54 that are required per the label with SPRAVATO.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “COMP360 expected to be a blockbuster opportunity with an estimated 4 million people in the U.S. living with TRD, a significantly underserved market where the only marketed medicine has captured <3% market share”

Source: [COMPASS Pathways third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm)

<a id="topic-2.1.2.14-4"></a>

### Session monitoring time compared with esketamine: six hours and two hours

> “From a site side, this will be very consistent with what they are already doing for SPRAVATO, outside of a couple of small tweaks that would be specific to the molecule itself, like the six hours versus two hours requirement.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.14-5"></a>

### Onset and durability: company statements on differentiation

> “Unlike any other approved treatment available for this patient population today, COMP360 may demonstrate effects as quickly as within one day after administration with durability lasting at least through 6 months for those who achieve a clinically meaningful response after one or two doses.”

Source: [COMPASS Pathways rolling review and voucher release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-FDA-Granted-NDA-Rolling-Review-Request-and-Awarded-Commissioners-National-Priority-Voucher/default.aspx)

> “COMP360's profile is unique and compellingly differentiated in delivering both a rapid onset, with effects seen within 24 hours, and durability potentially out to 12 months with just a few treatments.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.14-6"></a>

### TRD indication compared with psychedelics developed for major depressive disorder

> “If any of our competitors is granted an NDA for their psychedelic treatments before us and manages to obtain approval for a broader indication, such as major depressive disorder, and thus access a wider patient population, we may face more intensified competition from such potential psychedelic treatments and increased difficulties in winning market acceptance of our investigational COMP360 psilocybin treatment or any future therapeutic candidates.”
> “All of these risks are heightened because other psilocybin-based products, which may lack patent protection, may be deemed an appropriate substitute for COMP360.”

Source: [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)

> “We feel very confident and very good about the TRD data versus an MDD, more generalized population, and where that may land on formulary access, most importantly, in terms of rebating and formulary position.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.14-7"></a>

### Usona Institute psilocybin in major depressive disorder

> “In March 2024, Usona Institute announced the launch of its Phase 3 trial evaluating the efficacy and safety of psilocybin 25 mg as a treatment for major depressive disorder, which was expected to enroll approximately 240 adult patients, and Usona announced that it completed enrollment in its Phase 3 trial in November 2025.”
> “In April 2026, the FDA issued a National Priority Review voucher to Usona for its psilocybin as a treatment for major depressive disorder.”

Source: [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)

> “Trade publication Psychedelic Alpha reported Nov. 2 that the nonprofit Usona Institute had completed an NDA for its synthetic psilocybin in major depressive disorder (MDD), a broader patient population.”
> “Usona declined to comment to the publication.”

Source: [Drug Discovery and Development (2026)](https://www.drugdiscoverytrends.com/psychedelic-pioneer-compass-files-for-fda-approval-as-rivals-close-in/)

> “Before we turn to Q&A, let me acknowledge that we are aware of the recent speculation regarding another potential filing.”
> “There has been no official statement, and we will not be providing any comments on this matter.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.14-8"></a>

### Helus Pharma deuterated psilocin analog as adjunctive treatment of major depressive disorder

> “Helus Pharma is conducting a Phase 3 program for its proprietary novel serotonergic agonists (a proprietary deuterated psilocin analog) for the adjunctive treatment of major depressive disorder”

Source: [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)

> “Helus Pharma, formerly Cybin, expects topline data this quarter from APPROACH, the first of two Phase 3 trials of HLP003, a deuterated psilocin analog being tested as an add-on treatment for MDD.”
> “It is targeting an NDA in 2028.”

Source: [Drug Discovery and Development (2026)](https://www.drugdiscoverytrends.com/psychedelic-pioneer-compass-files-for-fda-approval-as-rivals-close-in/)

<a id="topic-2.1.2.14-9"></a>

### Other late-stage psychedelic candidates in depression and TRD

> “Definium Therapeutics, formerly MindMed, has reported three positive Phase 3 readouts for DT120, an orally disintegrating tablet formulation of LSD.”
> “The company reported results from Emerge in MDD in June, followed by Voyage and Panorama in generalized anxiety disorder (GAD).”
> “Two short-acting 5-MeO-DMT candidates for TRD come next.”
> “AtaiBeckley reported starting Phase 3 activities for its intranasal BPL-003 in the second quarter.”
> “GH Research has selected doses for a global Phase 3 program of its inhaled GH001.”

Source: [Drug Discovery and Development (2026)](https://www.drugdiscoverytrends.com/psychedelic-pioneer-compass-files-for-fda-approval-as-rivals-close-in/)

> “We are aware that Supernus Pharmaceuticals, Neurocrine Biosciences, GH Research and Beckley Psytech, among others, are developing treatments for TRD or inadequate response to treatment in major depressive disorder.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.2.14-10"></a>

### Polymorph patent coverage relative to other oral psilocybin products

> “As you know, it is directed to claims covering actually a number of polymorphs, and specifically the XRPD across those, and we are very confident that will withstand scrutiny from any other oral form of psilocybin.”
> “That extends to 2038 before patent term restoration, so we anticipate sort of 40, 41-ish probably.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.14-11"></a>

### REMS differences expected between psilocybin and MDMA

> “I obviously can't comment on how they're thinking about the class more generally, but I would stress that there are clearly key differences between, let's say, psilocybin and MDMA, and we clearly see that should be reflected in the REMS.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
